Women on testosterone report more than just a libido boost — energy and mood top the list. A retrospective survey of 332 women found 84% reported improved energy and fatigue, outranking sexual desire (67%). Meanwhile, the FDA is under pressure to approve a female-specific product as off-label prescriptions nearly tripled since 2023, and a separate observational study flags potential cardiovascular risks worth watching.
Women using testosterone therapy are reporting benefits well beyond the bedroom. A retrospective survey of 332 women (ages 27–78) on bloodwork-guided testosterone therapy found that energy and fatigue improvement topped the list at 84%, followed by depression (71%), irritability (69%), and sexual interest (67%). Cognitive gains — memory and concentration — emerged later, typically after 4–6 months of treatment. Overall, 90% of women reported improved quality of life, with significant improvement rising sharply with longer treatment duration.
The findings challenge the current clinical framing: existing guidelines (including the 2019 Global Consensus Statement and 2021 ISSWSH guideline) endorse testosterone only for hypoactive sexual desire disorder (HSDD) in postmenopausal women. But patients are clearly seeking — and reporting — much more. At the same time, a separate large retrospective cohort study raised a red flag, linking testosterone therapy in postmenopausal women to an 8-fold higher risk of cardiovascular events at 5 years, though researchers caution this is hypothesis-generating, not causal proof.
Key Takeaways:
Why it matters: With testosterone prescriptions for women surging and the FDA under growing pressure to act, clinicians are navigating a widening gap between patient demand, emerging evidence, and regulatory guidance — making shared decision-making and long-term safety research more critical than ever.
